A duodenal mass is any abnormal growth found in the duodenum, the short but critical first segment of the small intestine just past the stomach. These masses range from completely harmless nodules to aggressive cancers, and a single endoscopy report saying “duodenal mass” tells you almost nothing about severity until a biopsy or further imaging pins down the type. Understanding the main categories, how they announce themselves, and what treatment looks like for each can take a lot of the uncertainty out of that initial finding.
Why the Duodenum Is a Unique Neighborhood
The duodenum is only about 25 to 30 centimeters long, but it sits at a crossroads. Bile from the liver and digestive enzymes from the pancreas both empty into it through the ampulla of Vater, and the duodenal wall itself contains specialized Brunner’s glands that secrete alkaline mucus to neutralize stomach acid. That anatomical complexity means the duodenum can host a wider variety of mass types than you might expect from such a short stretch of bowel. Growths can arise from the mucosal lining, the glandular tissue, the muscle wall, hormone-producing cells, or even the ampulla itself. Each origin story points toward a different diagnosis and a different treatment plan.
Benign and Premalignant Masses
Most duodenal masses discovered incidentally during an upper endoscopy turn out to be benign. Brunner’s gland hamartomas are a good example: they are composed of an unusual mix of normal Brunner’s glands, fat cells, lymphoid tissue, and ductal tissue, and they do not show dysplasia, meaning the cells look normal under a microscope and carry essentially no cancer risk.1Clinical Endoscopy. Giant Brunner’s Gland Hamartoma of the Duodenal Bulb Presenting with Upper Gastrointestinal Bleeding and Obstruction Lipomas, inflammatory polyps, and small hyperplastic polyps also fall into this category. They may need removal if they grow large enough to bleed or block the intestinal passage, but they are not on a path to cancer.
Duodenal adenomas sit in a more worrying zone. These are premalignant growths: benign at the moment but capable of transforming into adenocarcinoma over time. Research shows that duodenal adenomas share molecular and structural features with colorectal adenomas, and the available data suggest they progress to cancer through similar step-by-step mechanisms.2PubMed Central. Nonampullary duodenal adenoma: Current understanding of its diagnosis, pathogenesis, and clinical management Roughly 40% of duodenal adenomas arise sporadically, while about 60% are linked to familial adenomatous polyposis (FAP). The risk of malignant conversion ranges widely depending on the adenoma’s features. Among patients with a solitary non-ampullary adenoma and only low-grade dysplasia, about 20% eventually develop high-grade dysplasia and roughly 5% develop noninvasive malignancy. But when high-grade dysplasia is already present and the lesion exceeds 2 cm, the risk climbs sharply, and immediate treatment is recommended.3Annals of Medicine and Surgery. Case series of non-ampullary duodenal adenomas The transformation from low-grade dysplasia to frank adenocarcinoma can take up to two decades, which is why surveillance programs exist for patients known to carry these adenomas.
Malignant Duodenal Tumors
Primary cancer of the duodenum is uncommon, but when it occurs it tends to be one of three main types: adenocarcinoma, neuroendocrine tumors, or gastrointestinal stromal tumors (GISTs). Each behaves differently and responds to different treatments.
Duodenal Adenocarcinoma
Adenocarcinoma is the most common primary duodenal cancer. It arises from the glandular lining, often progressing from an adenoma. Prognosis depends heavily on whether the cancer has spread to lymph nodes by the time it is found. A systematic review and meta-analysis of duodenal adenocarcinoma outcomes found that the five-year survival rate was about 65% when lymph nodes were free of cancer, but dropped to roughly 21% when nodes were involved.4PubMed Central. Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis Beyond nodal status, how deep the tumor invades matters enormously. A study reclassifying duodenal adenocarcinoma staging found that patients with tumors invading through the full thickness of the duodenal wall (pT4) had a dramatically worse outlook than earlier-stage tumors, regardless of whether one or two lymph nodes were positive. Among those with both pT4 invasion and extensive nodal disease (pN2), the five-year survival was only about 24%, and three-quarters of these patients developed distant metastases within the first year after surgery.5PubMed. Comparison of the clinical efficacy of a new prognostic stratification for duodenal adenocarcinoma with that of TNM staging
Neuroendocrine Tumors
Duodenal neuroendocrine tumors (D-NETs) arise from hormone-producing cells scattered through the duodenal wall. They are a heterogeneous group. Gastrinomas, which secrete the hormone gastrin and can cause severe peptic ulcer disease, make up roughly half to 60% of functioning D-NETs. Somatostatin-producing tumors account for about 15%, nonfunctional serotonin-containing tumors about 20%, and rarer subtypes like poorly differentiated neuroendocrine carcinomas and gangliocytic paragangliomas each make up only a few percent.6PubMed Central. Management of gastric and duodenal neuroendocrine tumors Many D-NETs are small. A multi-center retrospective study found that the majority were non-functioning tumors, with a median size of just 10 mm.7Scientific Reports. Diagnostic features and management options for duodenal neuroendocrine neoplasms: a retrospective, multi-centre study Small, well-differentiated, non-functioning D-NETs often have an excellent prognosis and can sometimes be managed endoscopically. Poorly differentiated neuroendocrine carcinomas, by contrast, behave aggressively and are treated more like other high-grade gastrointestinal cancers.
Gastrointestinal Stromal Tumors
GISTs originate from the interstitial cells of Cajal in the muscle layer of the gut wall. The duodenum is the second most common small-bowel site for GISTs after the jejunum. Nearly all GISTs express a protein called KIT on their surface. In one study of 94 GIST cases, about 97% stained positive for the KIT protein, while tumors that looked similar under the microscope but were actually leiomyomas or schwannomas did not express KIT at all, making it a useful diagnostic marker.8PubMed Central. Expression and mutation of c-kit gene in gastrointestinal stromal tumors About 40% of GISTs in that study carried mutations in a specific region of the c-kit gene, and patients whose tumors had those mutations experienced more frequent recurrences, invasion, and metastasis than those without them. This distinction is clinically important because targeted drug therapy can block the mutated protein.
How Duodenal Masses Cause Symptoms
Many duodenal masses are found by accident during endoscopies performed for unrelated reasons. When symptoms do appear, they tend to reflect the mass’s size and location more than whether it is benign or malignant. Common presentations include:
- Upper abdominal pain: a vague, gnawing discomfort that overlaps with peptic ulcer disease and is often investigated as such before the mass is found.
- Gastrointestinal bleeding: either slow occult bleeding that shows up as iron-deficiency anemia or, less often, visible blood in vomit or stool. Large Brunner’s gland hamartomas and adenomas both cause this.
- Nausea and vomiting: when a mass grows large enough to narrow the duodenal lumen, it creates a partial or complete gastric outlet obstruction. Meals cannot pass through, leading to recurrent vomiting of undigested food.
- Jaundice: masses near the ampulla of Vater can compress or invade the common bile duct, blocking bile drainage. One case report described jaundice caused by a gastric mass compressing the bile duct indirectly through a dilated, obstructed duodenum.9PubMed Central. A rare cause of obstructive jaundice and gastric outlet obstruction
- Weight loss: often a late sign, driven by obstruction, malabsorption, or the metabolic demands of a malignancy.
Functioning neuroendocrine tumors add their own layer. Gastrinomas trigger severe or refractory peptic ulcers (Zollinger-Ellison syndrome), while somatostatinomas can cause diabetes-like symptoms, gallstones, and fatty stools. These hormone-driven symptoms sometimes point clinicians toward the diagnosis before a mass is even seen on imaging.
Diagnostic Workup
Upper endoscopy with biopsy is the first-line investigation for most duodenal masses found during routine evaluation. The endoscopist can visually inspect the lesion, take tissue samples for pathology, and often determine whether the mass sits on the surface (mucosal) or beneath it (submucosal). For submucosal lesions, where a standard biopsy may miss the abnormal tissue entirely, endoscopic ultrasound (EUS) adds critical information. EUS can identify the layer of origin, the echo pattern, and the tissue consistency of a submucosal mass, which helps distinguish GISTs from lipomas, cysts, or other submucosal nodules.10PubMed Central. Endoscopic ultrasound-guided fine needle aspiration in submucosal lesion A separate study confirmed that ultrasound was useful in characterizing all submucosal duodenal lesions based on their echo level, layer of origin, and tissue homogeneity.11Gastrointestinal Endoscopy. Endosonographic characterization of duodenal elevated lesions
When staging is needed or when a mass may extend beyond the duodenal wall, cross-sectional imaging comes into play. Both CT enterography and MR enterography perform well at detecting small-bowel tumors. A meta-analysis reported pooled sensitivities above 90% for both techniques, with specificities in the low 80s.12PubMed Central. A systematic review and meta-analysis of magnetic resonance and computed tomography enterography in the diagnosis of small intestinal tumors However, a head-to-head prospective comparison found that MR enterography was significantly more sensitive than CT for detecting both overall small-bowel lesions (about 93% versus 76%) and neoplastic lesions specifically.13PubMed. Diagnosis of Small-Bowel Diseases: Prospective Comparison of Multi-Detector Row CT Enterography with MR Enterography In practice, CT is often used first because of its speed and availability, with MRI reserved for cases where more detail is needed or when radiation exposure is a concern.
Telling a Duodenal Tumor from a Pancreatic Invader
One diagnostic puzzle clinicians face is distinguishing a primary duodenal cancer from a pancreatic cancer that has grown into the duodenal wall. Pancreatic head tumors are far more common, and because the pancreas sits snug against the duodenum, invasion of the duodenal wall by pancreatic cancer is routine. Imaging features can help: one radiological study found that changes in mucosal folds were present in all cases of primary duodenal cancer, compared with about 86% of pancreatic cancers invading the duodenum. A thickened duodenal wall was seen in 84% of primary duodenal tumors, while luminal narrowing was found in about 52% of primary duodenal cancers versus only 26% of pancreatic cancers with duodenal involvement.14Symbiosis Online Publishing. Malignant Duodenal Lesion – Duodenal Tumor Vs Pancreatic Tumor – Semiological Radioimaging Characteristics None of these signs alone is definitive, but the pattern helps guide the surgical and treatment plan.
Endoscopic Treatment Options
For adenomas and some small neuroendocrine tumors, endoscopic removal can be curative without the need for major surgery. The main techniques include piecemeal snare resection (removing the lesion in fragments), endoscopic mucosal resection (EMR, where fluid is injected beneath the lesion to lift it before snaring), and endoscopic submucosal dissection (ESD, a more meticulous approach that cuts beneath the lesion as a single piece). ESD achieves high rates of en bloc resection, which is better for pathological assessment and reduces the chance of recurrence from residual tissue. The trade-off is safety: ESD in the duodenum carries a perforation risk of up to 39%, which is substantially higher than ESD in other parts of the gastrointestinal tract.15PubMed Central. Endoscopic Resection Techniques for Duodenal and Ampullary Adenomas The duodenal wall is thinner than the stomach or colon wall, and the bile and pancreatic fluid in the lumen complicate wound healing, which is why duodenal ESD is generally reserved for experienced centers.
For lesions that are too large, too sessile, or too suspicious for safe endoscopic removal, surgery becomes necessary. Endoscopic surveillance after incomplete removal is also standard, because adenoma recurrence after piecemeal resection is common and repeat procedures may be needed.
Surgical Approaches
The range of surgical options reflects how varied duodenal masses are. A small, localized lesion in the third or fourth portion of the duodenum might be treated with a limited segmental resection. For larger or more aggressive tumors, especially adenocarcinomas near the ampulla, the Whipple procedure (pancreaticoduodenectomy) remains the standard operation. It removes the duodenum, the head of the pancreas, the gallbladder, and the distal bile duct, then reconstructs the digestive tract. It is a major operation with significant complication rates, but for cancer involving the periampullary region, it offers the best chance of complete tumor removal.
For patients with widespread duodenal adenomatosis, particularly those with FAP who develop adenomas throughout the duodenum, a pancreas-preserving total duodenectomy (PPTD) is an alternative. A study comparing PPTD with the Whipple procedure found that hospital mortality was about 4% and overall complication rates were around 30% for PPTD. Importantly, no PPTD patients required long-term pancreatic enzyme supplementation, compared with all matched Whipple patients who did, because the pancreas is left intact.16ScienceDirect (The American Journal of Surgery). Is there an advantage in performing a pancreas-preserving total duodenectomy in duodenal adenomatosis? Preserving the pancreas means preserving both insulin production and digestive enzyme secretion, which has real quality-of-life benefits.
Targeted Therapy for GISTs
Duodenal GISTs that are unresectable or have already spread were historically very difficult to treat, because these tumors respond poorly to conventional chemotherapy. That changed with the introduction of imatinib mesylate, a drug that specifically blocks the tyrosine kinase protein that KIT mutations activate in GIST cells. Imatinib was one of the first successful targeted molecular therapies in oncology and transformed the treatment of advanced GIST from essentially palliative to potentially long-term disease control.17PubMed Central. Metastatic duodenal GIST: role of surgery combined with imatinib mesylate In some cases, imatinib is used before surgery to shrink a duodenal GIST down to a resectable size, potentially allowing a more limited operation. After surgery, adjuvant imatinib reduces the risk of recurrence in high-risk tumors.
Managing Obstruction in Advanced Disease
When a duodenal mass causes malignant gastric outlet obstruction and the cancer itself is not curable, the priority shifts to restoring the ability to eat. Two main palliative options exist: placing a self-expanding metal stent through the blocked segment, or creating a surgical bypass (gastrojejunostomy) that reroutes food around the blockage.
Both approaches successfully relieve the obstruction in the vast majority of patients. The trade-offs have to do with speed versus durability. A comparison found that patients who received stents resumed eating in about one day on average, while surgical bypass patients took about nine days, and stent patients were more likely to see an improvement in their overall performance status afterward.18PubMed. Comparison of duodenal stent placement with surgical gastrojejunostomy for palliation in patients with duodenal obstructions caused by pancreaticobiliary malignancies Stenting also means shorter hospital stays and lower costs. One study reported a median stay of 8 days for stenting versus 16 days for surgical bypass, with costs roughly halved.19PubMed Central. Stenting versus gastrojejunostomy for management of malignant gastric outlet obstruction: comparison of clinical outcomes and costs
But stents do not last forever. A comparative outcomes study found that the mean patency duration was about 97 days for stents versus about 169 days for surgical bypass, and overall survival trended longer in the surgery group as well.20Gastroenterology. Comparative Outcomes of Endoscopic Stenting and Surgical Gastrojejunostomy for Malignant Gastric Outlet Obstruction So the choice often depends on how long the patient is expected to live: stenting tends to suit patients with a shorter expected survival who benefit from the faster recovery, while a bypass makes more sense for patients who may live long enough to outlast a stent.
Hereditary Syndromes and Surveillance
Familial adenomatous polyposis is the hereditary condition most strongly linked to duodenal masses. People with FAP develop hundreds or thousands of polyps in the colon, but the duodenum is the second most common site of polyp formation, and duodenal cancer is the leading cause of death in FAP patients who have already had their colons removed. A related condition, MUTYH-associated polyposis (MAP), also carries elevated duodenal cancer risk.
Surveillance in these patients uses the Spigelman classification, a scoring system that accounts for the number of polyps, their size, their histology, and the degree of dysplasia. Higher Spigelman stages mean more frequent endoscopy and, at stage IV, discussion of prophylactic surgery. A validation study with ten years of follow-up showed that duodenal cancer developed in about 36% of patients with stage IV disease, compared with only about 2% in stages II and III.21Frontline Gastroenterology. Role of endoscopy in patients with familial adenomatous polyposis That said, the Spigelman system is not perfect. Cancer does occur in patients who have not reached stage IV, leading some researchers to argue that the scoring system should be modified to account for ampullary abnormalities that the current version underweights.22PubMed. Surveillance of Duodenal Polyposis in Familial Adenomatous Polyposis: Should the Spigelman Score Be Modified? A separate study confirmed that Spigelman stage IV does not precede most duodenal cancers in FAP, which means relying on it alone as a trigger for surgery may miss some patients who would benefit from earlier intervention.23Gastrointestinal Endoscopy. Spigelman stage IV duodenal polyposis does not precede most duodenal cancer cases in patients with familial adenomatous polyposis
Nutritional Aftereffects of Surgery
Removing part or all of the duodenum disrupts the normal digestive process. The duodenum is where most iron, calcium, and folate absorption takes place, and it is where pancreatic enzymes first mix with food. Patients who undergo a Whipple procedure or total duodenectomy frequently develop pancreatic exocrine insufficiency, meaning their pancreas can no longer deliver enough enzymes to properly break down food. This leads to fatty stools, bloating, and malabsorption of fat-soluble vitamins.
Pancreatic enzyme replacement therapy (PERT) is a mainstay of postoperative management. A study examining PERT use after upper gastrointestinal surgery found that most patients who needed it started within the first month after their operation, with dosages ranging from 50,000 to 125,000 international units. The majority of patients remained on PERT long term, though about a quarter stopped within six months because they either found no benefit or could not tolerate the supplements.24British Journal of Surgery. OGC P22 The Prevalence of Malabsorption and Use of Pancreatic Enzyme Replacement Therapy Post Upper GI Surgery Lifelong monitoring of vitamin and mineral levels, along with dietary adjustments like eating smaller, more frequent meals, becomes part of the routine for many of these patients.
Artificial Intelligence in Polyp Detection
For patients with FAP who undergo regular duodenal surveillance, one of the practical challenges is that the sheer number of polyps makes it easy for an endoscopist to miss some. An AI model developed specifically to identify duodenal polyps in FAP patients was tested against manual counts and found that it correctly identified about 79% of all polyps across the test images. On about 69% of images, the model missed zero polyps entirely. The polyps the model missed tended to be much smaller than the ones it caught, with missed polyps averaging about a third the diameter of detected ones. False positives occurred in about 46% of images, at a rate of less than one false polyp per image on average.25PubMed Central. Development of an artificial intelligence model to identify duodenal polyps in patients with familial adenomatous polyposis The technology is still early-stage, but the idea is that AI could serve as a second set of eyes during surveillance endoscopies, flagging tiny polyps that a human observer might overlook in a field crowded with lesions. Whether that translates into fewer missed cancers will require prospective clinical trials, but the initial performance suggests the approach is worth pursuing.